NIR absorptive croconic acid/quercetin/CaO 2 nanoplatform for tumor calcium overload therapy combined mild photothermal therapy
Biomaterials Advances, ISSN: 2772-9508, Vol: 149, Page: 213418
2023
- 9Citations
- 2Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef1
- Captures2
- Readers2
- Mentions1
- News Mentions1
- News1
Most Recent News
Researchers from Hangzhou Medical College Report New Studies and Findings in the Area of Nanoplatforms (Nir Absorptive Croconic Acid/quercetin/cao2 Nanoplatform for Tumor Calcium Overload Therapy Combined Mild Photothermal Therapy)
2023 SEP 07 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Researchers detail new data in Nanotechnology - Nanoplatforms. According to
Article Description
With excellent biocompatibility, stable chemical and optical properties, small organic molecules-based agents have always been a research hotspot in cancer photothermal therapy (PTT). In this work, a novel croconic acid-based molecule (CR) was designed and synthesized as an ideal photothermal agent (PTA), which showed abundant near-infrared (NIR) light absorption, high photothermal conversion ability, and excellent photothermal stability. By loading CR and quercetin (Qu) in CaO 2, and coated with DSPE-PEG 2000, a multifunctional theranostic nanoparticle (CCQ) was successfully prepared for calcium overloading mitochondrial metabolism inhibition synergetic mild PTT. Upon entering tumor microenvironment, CCQ can produce abundant H 2 O 2 and a large amount of calcium ions, which lead to the imbalance of calcium concentration in the internal environment of tumor cells and induced mitochondrial apoptosis. With the existence of Qu, CCQ can effectively inhibit the expression of heat shock proteins (Hsp) during the PTT process, which weaken the heat resistance of tumors, ablate tumors at lower temperature (~45 °C), and reduce the damage to normal tissues. Guided by photoacoustic imaging (PAI), CCQ showed excellent multimodal therapeutic effect of tumors. This study provided a novel CR organic molecule-based theranostic nanoplatform that can be used to treat tumors via calcium overload therapy synergetic PTT at safe temperatures, which has promising potential for the future clinical cancer treatment.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2772950823001413; http://dx.doi.org/10.1016/j.bioadv.2023.213418; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85152433384&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37062124; https://linkinghub.elsevier.com/retrieve/pii/S2772950823001413; https://dx.doi.org/10.1016/j.bioadv.2023.213418
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know